1
|
Cohen SM. Cell proliferation and carcinogenesis: an approach to screening for potential human carcinogens. Front Oncol 2024; 14:1394584. [PMID: 38868530 PMCID: PMC11168196 DOI: 10.3389/fonc.2024.1394584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2024] [Accepted: 04/22/2024] [Indexed: 06/14/2024] Open
Abstract
Cancer arises from multiple genetic errors occurring in a single stem cell (clonality). Every time DNA replicates, mistakes occur. Thus, agents can increase the risk of cancer either by directly damaging DNA (DNA-reactive carcinogens) or increasing the number of DNA replications (increased cell proliferation). Increased cell proliferation can be achieved either by direct mitogenesis or cytotoxicity with regenerative proliferation. Human carcinogens have a mode of action of DNA reactivity, immunomodulation (mostly immunosuppression), increased estrogenic activity (mitogenesis), or cytotoxicity and regeneration. By focusing on screening for these four effects utilizing in silico, in vitro, and short-term in vivo assays, a biologically based screening for human chemical carcinogens can be accomplished with greater predictivity than the traditional 2-year bioassay with considerably less cost, less time, and the use of fewer animals.
Collapse
Affiliation(s)
- Samuel M. Cohen
- Havlik-Wall Professor of Oncology, Department of Pathology, Microbiology, and Immunology and the Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, United States
| |
Collapse
|
2
|
Klaunig JE, Bevan C, Gollapudi B. Assessment of the mode of action of perchloroethylene-induced mouse liver tumors. Toxicol Ind Health 2024; 40:272-291. [PMID: 38523547 DOI: 10.1177/07482337241240188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/26/2024]
Abstract
Perchloroethylene (PCE) is used as a solvent and chemical intermediate. Following chronic inhalation exposure, PCE selectively induced liver tumors in mice. Understanding the mode of action (MOA) for PCE carcinogenesis in mice is important in defining its possible human cancer risk. The proposed MOA is based on the extensive examination of the peer-reviewed studies that have assessed the mouse liver effects of PCE and its major oxidative metabolite trichloroacetic acid (TCA). Similar to PCE, TCA has also been demonstrated to liver tumors selectively in mice following chronic exposure. The Key Events (KE) of the proposed PCE MOA involve oxidative metabolism of PCE to TCA [KE 1]; activation of the peroxisome proliferator-activated receptor alpha (PPARα) [KE 2]; alteration in hepatic gene expression including cell growth pathways [KE 3]; increase in cell proliferation [KE 4]; selective clonal expansion of hepatic preneoplastic foci [KE 5]; and formation of hepatic neoplasms [KE 6]. The scientific evidence supporting the PPARα MOA for PCE is strong and satisfies the requirements for a MOA analysis. The PPARα liver tumor MOA in rodents has been demonstrated not to occur in humans; thus, human liver cancer risk to PCE is not likely.
Collapse
Affiliation(s)
- James E Klaunig
- School of Public Health, Indiana University, Bloomington, IN, USA
| | | | | |
Collapse
|
3
|
Bates CA, Haber LT, Moore MM, Schoeny R, Maier A. Development of a framework for risk assessment of dietary carcinogens. Food Chem Toxicol 2023; 180:114022. [PMID: 37716495 DOI: 10.1016/j.fct.2023.114022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2022] [Revised: 08/09/2023] [Accepted: 09/01/2023] [Indexed: 09/18/2023]
Abstract
Although there are a number of guidance documents and frameworks for evaluation of carcinogenicity, none of the current methods fully reflects the state of the science. Common limitations include the absence of dose-response assessment and not considering the impact of differing exposure patterns (e.g., intermittent, high peaks vs. lower, continuous exposures). To address these issues, we have developed a framework for risk assessment of dietary carcinogens. This framework includes an enhanced approach for weight of evidence (WOE) evaluation for genetic toxicology data, with a focus on evaluating studies based on the most recent testing guidance to determine whether a chemical is a mutagen. Included alongside our framework is a discussion of resources for evaluating tissue dose and the temporal pattern of internal dose, taking into account the chemical's toxicokinetics. The framework then integrates the mode of action (MOA) and associated dose metric category with the exposure data to identify the appropriate approach(es) to low-dose extrapolation and level of concern associated with the exposure scenario. This framework provides risk managers with additional flexibility in risk management and risk communication options, beyond the binary choice of linear low-dose extrapolation vs. application of uncertainty factors.
Collapse
Affiliation(s)
| | - Lynne T Haber
- Risk Science Center, University of Cincinnati College of Medicine, USA
| | | | | | | |
Collapse
|
4
|
Strupp C, Corvaro M, Cohen SM, Corton JC, Ogawa K, Richert L, Jacobs MN. Increased Cell Proliferation as a Key Event in Chemical Carcinogenesis: Application in an Integrated Approach for the Testing and Assessment of Non-Genotoxic Carcinogenesis. Int J Mol Sci 2023; 24:13246. [PMID: 37686053 PMCID: PMC10488128 DOI: 10.3390/ijms241713246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2023] [Revised: 08/17/2023] [Accepted: 08/24/2023] [Indexed: 09/10/2023] Open
Abstract
In contrast to genotoxic carcinogens, there are currently no internationally agreed upon regulatory tools for identifying non-genotoxic carcinogens of human relevance. The rodent cancer bioassay is only used in certain regulatory sectors and is criticized for its limited predictive power for human cancer risk. Cancer is due to genetic errors occurring in single cells. The risk of cancer is higher when there is an increase in the number of errors per replication (genotoxic agents) or in the number of replications (cell proliferation-inducing agents). The default regulatory approach for genotoxic agents whereby no threshold is set is reasonably conservative. However, non-genotoxic carcinogens cannot be regulated in the same way since increased cell proliferation has a clear threshold. An integrated approach for the testing and assessment (IATA) of non-genotoxic carcinogens is under development at the OECD, considering learnings from the regulatory assessment of data-rich substances such as agrochemicals. The aim is to achieve an endorsed IATA that predicts human cancer better than the rodent cancer bioassay, using methodologies that equally or better protect human health and are superior from the view of animal welfare/efficiency. This paper describes the technical opportunities available to assess cell proliferation as the central gateway of an IATA for non-genotoxic carcinogenicity.
Collapse
Affiliation(s)
| | | | - Samuel M. Cohen
- Department of Pathology and Microbiology and Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA
| | - J. Christopher Corton
- Center for Computational Toxicology and Exposure, United States Environmental Protection Agency (US EPA), Research Triangle Park, NC 27711, USA;
| | - Kumiko Ogawa
- Division of Pathology, National Institute of Health Sciences, Kawasaki 210-9501, Japan
| | | | - Miriam N. Jacobs
- United Kingdom Health Security Agency (UK HSA), Radiation, Chemicals and Environmental Hazards, Harwell Innovation Campus, Dicot OX11 0RQ, UK
| |
Collapse
|
5
|
Berry SCL, Cohen SM, Corton JC, de Camargo JLV, Eisenbrand G, Fukushima S, Greim H, Weber K, Rietjens IMCM, Strupp C. Letter to the Editors regarding "10% body weight (gain) change as criterion for the maximum tolerated dose: A critical analysis". Regul Toxicol Pharmacol 2023; 139:105362. [PMID: 36828242 DOI: 10.1016/j.yrtph.2023.105362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Accepted: 02/15/2023] [Indexed: 02/24/2023]
Affiliation(s)
| | - Samuel M Cohen
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
| | - J Christopher Corton
- Center for Computational Toxicology and Exposure, Office of Research and Development, Environmental Protection Agency, Durham, NC, 27711, USA
| | | | - Gerhard Eisenbrand
- Department of Chemistry, Div of Food Chemistry & Toxicology, University of Kaiserslautern, Heidelberg, Germany
| | | | | | | | - Ivonne M C M Rietjens
- Division of Toxicology, Wageningen University and Research, Wageningen, the Netherlands
| | | |
Collapse
|
6
|
Harrison DJ, Doe JE. The modification of cancer risk by chemicals. Toxicol Res (Camb) 2021; 10:800-809. [PMID: 34484671 DOI: 10.1093/toxres/tfab064] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2021] [Revised: 05/13/2021] [Accepted: 06/17/2021] [Indexed: 12/30/2022] Open
Abstract
Advances in understanding of the process of carcinogenesis have undermined the concept of chemicals being classifiable as either carcinogens or non-carcinogens. Elements of carcinogenesis are happening all the time and a proportion of cancers cannot be prevented, the 'bad luck hypothesis'. Although the proportion that can be prevented is disputed, it is important to continue efforts to reduce it. Factors that increase cancer risk have been grouped into intrinsic factors that cannot be modified, and endogenous and exogenous factors that can be modified. Chemicals are exogenous factors that can be modified by risk management measures. Chemicals can alter three key rates that influence cancer risk: cell division, mutation rate per cell division, transformation rate of mutated cells to cancer. These rates can form the basis of a dynamic cancer risk model, a generic, adverse outcome pathway for carcinogenesis where chemicals are considered for their ability to modify cancer risk rather than simply whether they are classed as carcinogens or non-carcinogens. This allows the development of different strategies for assessing cancer risk that use a range of data sources and are not dependent on using long-term bioassays and epidemiology to identify carcinogens. The framework will also allow difficult questions such as the effect of less than lifetime exposures and the effect of exposures to more than one chemical to be addressed.
Collapse
Affiliation(s)
- David J Harrison
- School of Medicine, University of St Andrews, North Haugh, St Andrews KY16 9TF, UK
| | - John E Doe
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, UK
| |
Collapse
|
7
|
Thompson CM, Gentry R, Fitch S, Lu K, Clewell HJ. An updated mode of action and human relevance framework evaluation for Formaldehyde-Related nasal tumors. Crit Rev Toxicol 2021; 50:919-952. [PMID: 33599198 DOI: 10.1080/10408444.2020.1854679] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Formaldehyde is a reactive aldehyde naturally present in all plant and animal tissues and a critical component of the one-carbon metabolism pathway. It is also a high production volume chemical used in the manufacture of numerous products. Formaldehyde is also one of the most well-studied chemicals with respect to environmental fate, biology, and toxicology-including carcinogenic potential, and mode of action (MOA). In 2006, a published MOA for formaldehyde-induced nasal tumors in rats concluded that nasal tumors were most likely driven by cytotoxicity and regenerative cell proliferation, with possible contributions from direct genotoxicity. In the past 15 years, new research has better informed the MOA with the publication of in vivo genotoxicity assays, toxicogenomic analyses, and development of ultra-sensitive methods to measure endogenous and exogenous formaldehyde-induced DNA adducts. Herein, we review and update the MOA for nasal tumors, with particular emphasis on the numerous studies published since 2006. These new studies further underscore the involvement of cytotoxicity and regenerative cell proliferation, and further inform the genotoxic potential of inhaled formaldehyde. The data lend additional support for the use of mechanistic data for the derivation of toxicity criteria and/or scientifically supported approaches for low-dose extrapolation for the risk assessment of formaldehyde.
Collapse
Affiliation(s)
| | | | | | - Kun Lu
- Department of Environmental Sciences and Engineering, University of North Carolina at Chapel Hill, NC, USA
| | | |
Collapse
|
8
|
Yamada T, Cohen SM, Lake BG. Critical evaluation of the human relevance of the mode of action for rodent liver tumor formation by activators of the constitutive androstane receptor (CAR). Crit Rev Toxicol 2021; 51:373-394. [PMID: 34264181 DOI: 10.1080/10408444.2021.1939654] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Many nongenotoxic chemicals have been shown to produce liver tumors in mice and/or rats by a mode of action (MOA) involving activation of the constitutive androstane receptor (CAR). Studies with phenobarbital (PB) and other compounds have identified the key events for this MOA: CAR activation; increased hepatocellular proliferation; altered foci formation; and ultimately the development of adenomas/carcinomas. In terms of human relevance, the pivotal species difference is that CAR activators are mitogenic agents in mouse and rat hepatocytes, but they do not stimulate increased hepatocellular proliferation in humans. This conclusion is supported by substantial in vitro studies with cultured rodent and human hepatocytes and also by in vivo studies with chimeric mice with human hepatocytes. Examination of the literature reveals many similarities in the hepatic effects and species differences between activators of rodent CAR and the peroxisome proliferator-activated receptor alpha (PPARα), with PPARα activators also not being mitogenic agents in human hepatocytes. Overall, a critical analysis of the available data demonstrates that the established MOA for rodent liver tumor formation by PB and other CAR activators is qualitatively not plausible for humans. This conclusion is supported by data from several human epidemiology studies.
Collapse
Affiliation(s)
- Tomoya Yamada
- Environmental Health Science Laboratory, Sumitomo Chemical Company, Ltd., Osaka, Japan
| | - Samuel M Cohen
- Department of Pathology and Microbiology, Havlik-Wall Professor of Oncology, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE, USA
| | - Brian G Lake
- Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
| |
Collapse
|
9
|
Cohen JM, Beck BD, Rhomberg LR. Historical perspective on the role of cell proliferation in carcinogenesis for DNA-reactive and non-DNA-reactive carcinogens: Arsenic as an example. Toxicology 2021; 456:152783. [PMID: 33872731 DOI: 10.1016/j.tox.2021.152783] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Revised: 04/07/2021] [Accepted: 04/11/2021] [Indexed: 10/21/2022]
Abstract
Our understanding of the etiology of cancer has developed significantly over the past fifty years, beginning with a single-hit linear no-threshold (LNT) conceptual model based on early studies conducted in Drosophila. Over the past several decades, multiple lines of evidence have accumulated to support a contemporary model of chemical carcinogenesis: a multi-hit model involving a prolonged stress environment that over time may drive the mutation of multiple cells into an injured state that ultimately could lead to uncontrolled proliferation via clonal expansion of mutation-carrying daughter cells. Arsenic carcinogenicity offers a useful case study for further exploration of advanced conceptual models for chemical carcinogenesis. A threshold for arsenic carcinogenicity is supported by its mode of action, characterized by repeating cycles of cytotoxicity and cellular regeneration. Furthermore, preliminary meta-analyses of epidemiology dose-response data for inorganic arsenic (iAs) and bladder cancer, correlated to dose-response data measured in vitro, support a threshold of effect in humans on the order of 50-100 μg/L in drinking water. In light of recent developments in our understanding of cancer etiology, we urge strong consideration of the existing mode-of-action evidence supporting a threshold of effect for arsenic carcinogenicity, as well as consideration of the potential methodological pitfalls in evaluating epidemiology dose-response data that could potentially bias in the direction of low-dose linearity.
Collapse
|
10
|
Smith CJ, Perfetti TA, Berry SC, Brash DE, Bus J, Calabrese E, Clemens RA, Fowle JRJ, Greim H, MacGregor JT, Maronpot R, Pressman P, Zeiger E, Hayes AW. Bruce Nathan Ames - Paradigm shifts inside the cancer research revolution. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH 2020; 787:108363. [PMID: 34083041 DOI: 10.1016/j.mrrev.2020.108363] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/07/2020] [Revised: 12/21/2020] [Accepted: 12/22/2020] [Indexed: 11/26/2022]
Abstract
Dr. Bruce Ames turned 92 on December 16, 2020. He considers his most recent work linking adequate consumption of 30 known vitamins and minerals with successful aging to be his most important contribution. With the passage of time, it is not uncommon for the accomplishments of a well-known scientist to undergo a parsimonious reductionism in the public mind - Pasteur's vaccine, Mendel's peas, Pavlov's dogs, Ames' test. Those of us in the research generation subsequent to Dr. Ames' are undoubtedly affected by our own unconscious tendencies toward accepting the outstanding achievements of the past as commonplace. In doing so, seminal advances made by earlier investigators are often inadvertently subsumed into common knowledge. But having followed Ames' work since the mid-1970s, we are cognizant that the eponymous Ames Test is but a single chapter in a long and rich narrative. That narrative begins with Ames' classic studies on the histidine operon of Salmonella, for which he was elected to the National Academy of Sciences. A summary of the historical progression of the understanding of chemical carcinogenesis to which Ames and his colleagues contributed is provided. Any summary of a topic as expansive and complex as the ongoing unraveling of the mechanisms underlying chemical carcinogenesis will only touch upon some of the major conceptual advances to which Ames and his colleagues contributed. We hope that scientists of all ages familiar with Ames only through the eponymous Ames Test will further investigate the historical progression of the conceptualization of cancer caused by chemical exposure. As the field of chemical carcinogenesis gradually moves away from primary reliance on animal testing to alternative protocols under the rubric of New Approach Methodologies (NAM) an understanding of where we have been might help to guide where we should go.
Collapse
Affiliation(s)
| | | | | | - Douglas E Brash
- Yale University School of Medicine, Senior Research Scientist, Clinical Professor of Therapeutic Radiology, Professor of Genetics and Dermatology, New Haven, CT, USA
| | | | - Edward Calabrese
- University of Massachusetts, School of Public Health and Health Sciences, Professor of Toxicology, Amherst, MA, USA
| | - Roger A Clemens
- University of Southern California, Adjunct Professor of Pharmaceutical Sciences, Associate Director, Regulatory Science Program, USC School of Pharmacy, Los Angeles, CA, USA
| | | | - Helmut Greim
- Professor Emeritus of Toxicology and Environmental Hygiene, Technical University of Munich, Munich, Germany
| | | | | | | | | | - A Wallace Hayes
- University of South Florida College of Public Health Tampa, FL, USA; Institute for Integrative Toxicology, Michigan State University East Lansing, MI, USA
| |
Collapse
|
11
|
Bhat VS, Cohen SM, Gordon EB, Wood CE, Cullen JM, Harris MA, Proctor DM, Thompson CM. An adverse outcome pathway for small intestinal tumors in mice involving chronic cytotoxicity and regenerative hyperplasia: a case study with hexavalent chromium, captan, and folpet. Crit Rev Toxicol 2020; 50:685-706. [PMID: 33146058 DOI: 10.1080/10408444.2020.1823934] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Small intestinal (SI) tumors are relatively uncommon outcomes in rodent cancer bioassays, and limited information regarding chemical-induced SI tumorigenesis has been reported in the published literature. Herein, we propose a cytotoxicity-mediated adverse outcome pathway (AOP) for SI tumors by leveraging extensive target species- and site-specific molecular, cellular, and histological mode of action (MOA) research for three reference chemicals, the fungicides captan and folpet and the transition metal hexavalent chromium (Cr(VI)). The gut barrier functions through highly efficient homeostatic regulation of SI epithelial cell sloughing, regenerative proliferation, and repair, which involves the replacement of up to 1011 cells per day. This dynamic turnover in the SI provides a unique local environment for a cytotoxicity mediated AOP/MOA. Upon entering the duodenum, cytotoxicity to the villous epithelium is the molecular initiating event, as indicated by crypt elongation, villous atrophy/blunting, and other morphologic changes. Over time, the regenerative capacity of the gut epithelium to compensate declines as epithelial loss accelerates, especially at higher exposures. The first key event (KE), sustained regenerative crypt proliferation/hyperplasia, requires sufficient durations, likely exceeding 6 or 12 months, due to extensive repair capacity, to create more opportunities for the second KE, spontaneous mutation/transformation, ultimately leading to proximal SI tumors. Per OECD guidance, biological plausibility, essentiality, and empirical support were assessed using modified Bradford Hill considerations. The weight-of-evidence also included a lack of induced mutations in the duodenum after up to 90 days of Cr(VI) or captan exposure. The extensive evidence for this AOP, along with the knowledge that human exposures are orders of magnitude below those associated with KEs in this AOP, supports its use for regulatory applications, including hazard identification and risk assessment.
Collapse
Affiliation(s)
| | - Samuel M Cohen
- Havlik-Wall Professor of Oncology, Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA
| | | | - Charles E Wood
- Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA
| | - John M Cullen
- North Carolina State University, Raleigh, NC, USA.,EPL, Inc., Sterling, VA, USA
| | | | | | | |
Collapse
|
12
|
Lindauer K, Bartels T, Scherer P, Kabiri M. Development and Validation of an Image Analysis System for the Measurement of Cell Proliferation in Mammary Glands of Rats. Toxicol Pathol 2020; 47:634-644. [PMID: 31409263 DOI: 10.1177/0192623319863129] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Reliable detection and measurement of cell proliferation are essential in the preclinical assessment of carcinogenic risk of therapeutics. In this context, the assessment of mitogenic potential on mammary glands is crucial in the preclinical safety evaluation of novel insulins. The existing manual counting is time-consuming and subject to operator bias. To standardize the processes, make it faster, and resistant to errors, we developed a semiautomated image analysis system (CEPA software, which is open-source) for counting of proliferating cells in photomicrographs of mammary gland sections of rats labeled with Ki-67. We validated the software and met the predefined targets for specificity, accuracy, and reproducibility. In comparison to manual counting, the respective mean differences in absolute labeling indices (LIs) for CEPA software were 3.12% for user 1 and 3.05% for user 2. The respective regression analysis revealed a good correlation between the CEPA software user and manual counting. Moreover, the CEPA software showed enhanced reproducibility between independent users. The interuser variability is centered around 0 and the absolute difference was about 0.53% LI. Based on validation data, our software has superiority to the manual counting and is a valid and reliable tool for the routine analysis of cell proliferation in mammary glands from rats exposed to insulin analogs.
Collapse
Affiliation(s)
- Klaus Lindauer
- 1 Sanofi-Aventis Deutschland GmbH, R&D TMED PKDM, Frankfurt, Germany.,The first two authors contributed equally to this work
| | - Thomas Bartels
- 2 Sanofi France, R&D Preclinical Safety, Pathology, Paris, France.,The first two authors contributed equally to this work
| | - Petra Scherer
- 3 Sanofi-Aventis Deutschland GmbH, R&D TIM Global Discovery Pathology, Frankfurt, Germany
| | - Mostafa Kabiri
- 4 Sanofi-Aventis Deutschland GmbH, R&D TIM Transgenic Models and Technology, Frankfurt, Germany
| |
Collapse
|
13
|
Felter SP, Boobis AR, Botham PA, Brousse A, Greim H, Hollnagel HM, Sauer UG. Hazard identification, classification, and risk assessment of carcinogens: too much or too little? - Report of an ECETOC workshop. Crit Rev Toxicol 2020; 50:72-95. [PMID: 32133908 DOI: 10.1080/10408444.2020.1727843] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
The European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) organized a workshop "Hazard Identification, Classification and Risk Assessment of Carcinogens: Too Much or Too Little?" to explore the scientific limitations of the current binary carcinogenicity classification scheme that classifies substances as either carcinogenic or not. Classification is often based upon the rodent 2-year bioassay, which has scientific limitations and is not necessary to predict whether substances are likely human carcinogens. By contrast, tiered testing strategies founded on new approach methodologies (NAMs) followed by subchronic toxicity testing, as necessary, are useful to determine if a substance is likely carcinogenic, by which mode-of-action effects would occur and, for non-genotoxic carcinogens, the dose levels below which the key events leading to carcinogenicity are not affected. Importantly, the objective is not for NAMs to mimic high-dose effects recorded in vivo, as these are not relevant to human risk assessment. Carcinogenicity testing at the "maximum tolerated dose" does not reflect human exposure conditions, but causes major disturbances of homeostasis, which are very unlikely to occur at relevant human exposure levels. The evaluation of findings should consider biological relevance and not just statistical significance. Using this approach, safe exposures to non-genotoxic substances can be established.
Collapse
Affiliation(s)
| | | | | | - Alice Brousse
- European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC), Brussels, Belgium
| | | | | | - Ursula G Sauer
- Scientific Consultancy - Animal Welfare, Neubiberg, Germany
| |
Collapse
|
14
|
Smith CJ, Perfetti TA. High-dose exposure to synthetic chemicals, hormones, or homeostatic substances in experimental animals or humans can induce artefactual pathology. TOXICOLOGY RESEARCH AND APPLICATION 2020. [DOI: 10.1177/2397847320940557] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
The maximum tolerated dose (MTD) provides the highest probability of a positive result in a toxicology bioassay. The assumption underlying the MTD in animal bioassays is that adverse effects at very high doses are qualitatively the same as those occurring at low doses. In contrast with the MTD, the optimal top dose in a toxicology animal study is the highest dose that does not produce a pathological end point that presents no risk at lower doses, for example, the dose below which cytotoxicity induces tumors in the absence of genotoxicity or other carcinogenic mechanisms. Normal concentrations or biological activity levels of many substances necessary for normal physiological function induce pathology when found at high levels. For example, the demonstration that ingestion of abnormally high levels of certain dietary fats can cause or exacerbate atherosclerosis in relevant animal models like rhesus macaques does not demonstrate that normal levels of these fats should be considered as toxic. Excessive estrogenic stimulation is associated with breast, ovarian, and endometrial cancers. This does not imply that normal age-appropriate levels of estrogen are toxic. Normal wound healing is associated with transforming growth factors beta 1 and 2. Excessive stimulation of fibroblasts by these growth factors results in hypertrophic scarring and keloid formation. An understanding of the mode of action of a test substance can facilitate the selection of dose levels much higher than those expected to be experienced by humans, but not beyond a dose level at which pathology is an experimental artefact of the high-dose level.
Collapse
|
15
|
Berry CL, Cohen SM, Hayes AW, Kaminski NE. The NTP 2-year bioassay: Controversies in counting rodent tumors to predict human cancer. TOXICOLOGY RESEARCH AND APPLICATION 2019. [DOI: 10.1177/2397847319889535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
16
|
Smith CJ, Perfetti TA. In vitro cobalt-stimulated hypoxia-inducible factor-1 overexpression does not correlate with cancer risk from cobalt exposure in humans. TOXICOLOGY RESEARCH AND APPLICATION 2019. [DOI: 10.1177/2397847319850167] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Affiliation(s)
- Carr J Smith
- Albemarle Corporation, Mobile, AL, USA
- Department of Nurse Anesthesia, Florida State University, Tallahassee, FL, USA
| | | |
Collapse
|
17
|
Cohen SM, Boobis AR, Dellarco VL, Doe JE, Fenner-Crisp PA, Moretto A, Pastoor TP, Schoeny RS, Seed JG, Wolf DC. Chemical carcinogenicity revisited 3: Risk assessment of carcinogenic potential based on the current state of knowledge of carcinogenesis in humans. Regul Toxicol Pharmacol 2019; 103:100-105. [DOI: 10.1016/j.yrtph.2019.01.017] [Citation(s) in RCA: 45] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2018] [Revised: 01/04/2019] [Accepted: 01/07/2019] [Indexed: 01/27/2023]
|
18
|
Bronchioloalveolar lung tumors induced in “mice only” by non-genotoxic chemicals are not useful for quantitative assessment of pulmonary adenocarcinoma risk in humans. TOXICOLOGY RESEARCH AND APPLICATION 2018. [DOI: 10.1177/2397847318816617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Chemicals classified as known human carcinogens by International Agency for Research on Cancer (IARC) show a low level of concordance between rodents and humans for induction of pulmonary carcinoma. Rats and mice exposed via inhalation for 2 years show a low level of concordance in both tumor development and organ site location. In 2-year inhalation studies using rats and mice, when pulmonary tumors are seen in only male or female mice or both, but not in either sex of rat, there is a high probability that the murine pulmonary tumor has been produced via Clara cell or club cell (CC) metabolism of the inhaled chemical to a cytotoxic metabolite. Cytotoxicity-induced mitogenesis increases mutagenesis via amplification of the background mutation rate. If the chemical being tested is also negative in the Ames Salmonella mutagenicity assay, and only mouse pulmonary tumors are induced, the probability that this pulmonary tumor is not relevant to human lung cancer risk goes even higher. Mice have a larger percentage of CCs in their distal airways than rats, and a much larger percentage than in humans. The CCs of mice have a much higher concentration of metabolic enzymes capable of metabolizing xenobiotics than CCs in either rats or humans. A principal threat to validity of extrapolating from the murine model lies in the unique capacity of murine CCs to metabolize a significant spectrum of xenobiotics which in turn produces toxicants not seen in rat or human pulmonary pathophysiology.
Collapse
|
19
|
Cohen SM. Screening for human urinary bladder carcinogens: two-year bioassay is unnecessary. Toxicol Res (Camb) 2018; 7:565-575. [PMID: 30090607 PMCID: PMC6061447 DOI: 10.1039/c7tx00294g] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2017] [Accepted: 01/22/2018] [Indexed: 11/21/2022] Open
Abstract
Screening for carcinogens in general, and for the urinary bladder specifically, traditionally involves a two-year bioassay in rodents, the results of which often do not have direct relevance to humans with respect to mode of action (MOA) and/or dose response. My proposal describes a multi-step short-term (90 day) screening process that characterizes known human urinary bladder carcinogens, and identifies those reported in rodent two-year bioassays. The initial step is screening for urothelial proliferation, by microscopy or by increased Ki-67 labeling index. If these are negative, the agent is not a urinary bladder carcinogen. If either of these is positive, an MOA and dose response analysis are performed. DNA reactivity is evaluated. If the chemical is non-DNA reactive, evaluation for cytotoxicity is performed. This involves examination of the urothelium and urine, the latter to identify the generation of urinary solids (e.g. calculi). If urinary solids are the cause of cytotoxicity, the MOA is not relevant to human cancer, but dose response becomes essential for evaluating potential toxicity to humans. If cytotoxicity occurs but no urinary solids are detected, urinary concentrations of the chemical and its metabolites are evaluated, and compared to in vitro cytotoxicity against rodent and human immortalized urothelial cell lines. Based on this process, a screen for urinary bladder carcinogenicity is reliable, and more importantly, can be based on MOA and dose response analyses useful in the overall risk assessment for possible human bladder cancer. The proposed procedure is shorter, less expensive and more relevant than the two-year bioassay.
Collapse
Affiliation(s)
- Samuel M Cohen
- Havlik-Wall Professor of Oncology , Department of Pathology and Microbiology , University of Nebraska Medical Center , Omaha , NE 68198-3135 , USA .
| |
Collapse
|
20
|
Braakhuis HM, Slob W, Olthof ED, Wolterink G, Zwart EP, Gremmer ER, Rorije E, van Benthem J, Woutersen R, van der Laan JW, Luijten M. Is current risk assessment of non-genotoxic carcinogens protective? Crit Rev Toxicol 2018; 48:500-511. [PMID: 29745287 DOI: 10.1080/10408444.2018.1458818] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
Non-genotoxic carcinogens (NGTXCs) do not cause direct DNA damage but induce cancer via other mechanisms. In risk assessment of chemicals and pharmaceuticals, carcinogenic risks are determined using carcinogenicity studies in rodents. With the aim to reduce animal testing, REACH legislation states that carcinogenicity studies are only allowed when specific concerns are present; risk assessment of compounds that are potentially carcinogenic by a non-genotoxic mode of action is usually based on subchronic toxicity studies. Health-based guidance values (HBGVs) of NGTXCs may therefore be based on data from carcinogenicity or subchronic toxicity studies depending on the legal framework that applies. HBGVs are usually derived from No-Observed-Adverse-Effect-Levels (NOAELs). Here, we investigate whether current risk assessment of NGTXCs based on NOAELs is protective against cancer. To answer this question, we estimated Benchmark doses (BMDs) for carcinogenicity data of 44 known NGTXCs. These BMDs were compared to the NOAELs derived from the same carcinogenicity studies, as well as to the NOAELs derived from the associated subchronic studies. The results lead to two main conclusions. First, a NOAEL derived from a subchronic study is similar to a NOAEL based on cancer effects from a carcinogenicity study, supporting the current practice in REACH. Second, both the subchronic and cancer NOAELs are, on average, associated with a cancer risk of around 1% in rodents. This implies that for those chemicals that are potentially carcinogenic in humans, current risk assessment of NGTXCs may not be completely protective against cancer. Our results call for a broader discussion within the scientific community, followed by discussions among risk assessors, policy makers, and other stakeholders as to whether or not the potential cancer risk levels that appear to be associated with currently derived HBGVs of NGXTCs are acceptable.
Collapse
Affiliation(s)
- Hedwig M Braakhuis
- a Centre for Health Protection , National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands
| | - Wout Slob
- b Centre for Nutrition, Prevention and Health services , National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands
| | - Evelyn D Olthof
- a Centre for Health Protection , National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands
| | - Gerrit Wolterink
- b Centre for Nutrition, Prevention and Health services , National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands
| | - Edwin P Zwart
- a Centre for Health Protection , National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands
| | - Eric R Gremmer
- a Centre for Health Protection , National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands
| | - Emiel Rorije
- c Centre for Safety of Substances and Products , National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands
| | - Jan van Benthem
- a Centre for Health Protection , National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands
| | - Ruud Woutersen
- d Netherlands Organization for Applied Scientific Research (TNO) , Zeist , The Netherlands
| | | | - Mirjam Luijten
- a Centre for Health Protection , National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands
| |
Collapse
|
21
|
Proctor DM, Suh M, Chappell G, Borghoff SJ, Thompson CM, Wiench K, Finch L, Ellis-Hutchings R. An Adverse Outcome Pathway (AOP) for forestomach tumors induced by non-genotoxic initiating events. Regul Toxicol Pharmacol 2018; 96:30-40. [PMID: 29684431 DOI: 10.1016/j.yrtph.2018.04.016] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2018] [Revised: 04/15/2018] [Accepted: 04/18/2018] [Indexed: 02/07/2023]
Abstract
The utility of rodent forestomach tumor data for hazard and risk assessment has been examined for decades because humans do not have a forestomach, and these tumors occur by varying modes of action (MOAs). We have used the MOA for ethyl acrylate (EA) to develop an Adverse Outcome Pathway (AOP) for forestomach tumors caused by non-genotoxic initiating events. These tumors occur secondary to site of contact induced epithelial cytotoxicity and regenerative repair-driven proliferation. For EA, the critical initiating event (IE) is epithelial cytotoxicity, and supporting key events (KEs) at the cellular and tissue level are increased cell proliferation (KE1) resulting in sustained hyperplasia (KE2), with the adverse outcome of forestomach papillomas and carcinomas. For EA, a pre-molecular initiating event (pre-MIE) of sustained glutathione depletion is probable. Supporting data from butylated hydroxyanisole (BHA) are also reviewed. Although there may be some variability in the pre-MIEs and IEs for BHA and EA, they share the same KEs, and evidence for BHA confers support for the AOP. Evolved Bradford Hill considerations of biological plausibility, essentiality, and empirical support were evaluated per OECD guidance. Although an MIE is not specifically described, overall confidence in the AOP is high due to well-developed and accepted evidence streams, and the AOP can be used for regulatory applications including hazard identification and risk assessment for chemicals that act by this AOP.
Collapse
Affiliation(s)
| | - Mina Suh
- ToxStrategies, Inc., Mission Viejo, CA 92692, USA
| | | | | | | | | | | | | |
Collapse
|
22
|
Schrenk D. What is the meaning of 'A compound is carcinogenic'? Toxicol Rep 2018; 5:504-511. [PMID: 29854622 PMCID: PMC5977538 DOI: 10.1016/j.toxrep.2018.04.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2018] [Revised: 03/14/2018] [Accepted: 04/06/2018] [Indexed: 01/08/2023] Open
Abstract
Chemical Carcinogens are compounds which can cause cancer in humans and experimental animals. This property is attributed to many chemicals in the public discussion, resulting in a widespread perception of danger and threat. In contrast, a scientific analysis of the wide and non-critical use of the term 'carcinogenic' is warranted. First, it has to be clarified if the compound acts in a genotoxic or non-genotoxic manner. In the latter case, an ineffective (safe) threshold dose without cancer risk can be assumed. In addition, it needs to be investigated if the mode-of-action causing tumors in laboratory animals is relevant at all for humans. In case the compound is clearly directly genotoxic, an ineffective threshold dose cannot be assumed. However, also in this case it is evident that high doses of the compound are generally associated with a high cancer risk, low doses with a lower one. Based on dose-response data from animal experiments, quantification of the cancer risk is carried out by mathematical modeling. If the safety margin between the lowest carcinogenic dose in animals and the relevant level of exposure in humans exceeds 10,000, the degree of concern is classified as low. Cases, where the compound turns out to be genotoxic in one study or one test only but not in others or only in vitro but not in vivo, are particularly difficult to explain and cause controversial discussions. Also for indirectly genotoxic agents, an ineffective (threshold) dose must be assumed. The situation is aggravated by the use of doubtful epidemiological studies in humans such as in the case of glyphosate, where data from mixed exposure to various chemicals were used. If such considerations are mixed with pure hazard classifications such as 'probably carcinogenic in humans' ignoring dose-response behavior and mode-of-action, the misinformation and public confusion are complete. It appears more urgent but also more difficult than ever to return to a scientifically based perception of these issues.
Collapse
|
23
|
Cohen SM. Cell Proliferation in the Evaluation of Carcinogenic Risk and the Inadequacies of the Initiation-Promotion Model. Int J Toxicol 2016. [DOI: 10.1177/109158189801700310] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Samuel M. Cohen
- Department of Pathology and Microbiology, University
of Nebraska Medical Center, 600 S. 42nd Street, Omaha, Nebraska 68198-3135,
USA
| |
Collapse
|
24
|
Cohen SM, Chowdhury A, Arnold LL. Inorganic arsenic: A non-genotoxic carcinogen. J Environ Sci (China) 2016; 49:28-37. [PMID: 28007178 DOI: 10.1016/j.jes.2016.04.015] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2016] [Revised: 04/21/2016] [Accepted: 04/22/2016] [Indexed: 05/02/2023]
Abstract
Inorganic arsenic induces a variety of toxicities including cancer. The mode of action for cancer and non-cancer effects involves the metabolic generation of trivalent arsenicals and their reaction with sulfhydryl groups within critical proteins in various cell types which leads to the biological response. In epithelial cells, the response is cell death with consequent regenerative proliferation. If this continues for a long period of time, it can result in an increased risk of cancer. Arsenicals do not react with DNA. There is evidence for indirect genotoxicity in various in vitro and in vivo systems, but these involve exposures at cytotoxic concentrations and are not the basis for cancer development. The resulting markers of genotoxicity could readily be due to the cytotoxicity rather than an effect on the DNA itself. Evidence for genotoxicity in humans has involved detection of chromosomal aberrations, sister chromatid exchanges in lymphocytes and micronucleus formation in lymphocytes, buccal mucosal cells, and exfoliated urothelial cells in the urine. Numerous difficulties have been identified in the interpretation of such results, including inadequate assessment of exposure to arsenic, measurement of micronuclei, and potential confounding factors such as tobacco exposure, folate deficiency, and others. Overall, the data strongly supports a non-linear dose response for the effects of inorganic arsenic. In various in vitro and in vivo models and in human epidemiology studies there appears to be a threshold for biological responses, including cancer.
Collapse
Affiliation(s)
- Samuel M Cohen
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198-3135, USA.
| | - Aparajita Chowdhury
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198-3135, USA
| | - Lora L Arnold
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198-3135, USA
| |
Collapse
|
25
|
Strupp C, Bomann W, Cohen SM, Weber K. Relationship of Metabolism and Cell Proliferation to the Mode of Action of Fluensulfone-Induced Mouse Lung Tumors. II: Additional Mechanistic Studies. Toxicol Sci 2016; 154:296-308. [DOI: 10.1093/toxsci/kfw168] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Cohen SM, Ellwein LB. Cell Growth Dynamics in Bladder Carcinogenesis: Implications for Risk Assessment. ACTA ACUST UNITED AC 2016. [DOI: 10.3109/10915818909018070] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
A biological model of carcinogenesis has been developed that can be expressed mathematically, and therefore can be studied using computer-based analyses. It is based on several assumptions: Carcinogenesis occurs in two stages: initiation and transformation (to malignant tumors); the carcinogenic events can occur only in stem cells or their functional equivalents; these events can occur only during the active part of the cell cycle; each of the events occurs in a probabilistic fashion. Cell dynamics are thus an extremely important part of carcinogenesis. Any agent can have an impact on the carcinogenic process by either directly altering the genome (genotoxic) or increasing the proliferative rate of the tissues: increasing the number of cell divisions through which a spontaneous alteration in the genome can occur; or an agent can affect both of these. Effects on the genome and on cell proliferation can have different dose-responses. Extrapolation to low doses requires consideration of the dose-response for each effect. Differences in mechanisms affecting cell proliferation and genetic changes need to be considered in determining thresholds. The model was originally validated utilizing tumor incidence data from multiple experiments with the carcinogen, N-[4-(5-nitro-2-furyl)2-thiazolyl]-formamide (FANFT), in rats. FANFT is a strong mutagen, is metabolically activated to a reactive electrophile, binds to DNA, and also increases cell proliferation. Modeling analyses demonstrate that the tumor dose-response curve for FANFT can be explained based on a combination of the individual dose-response of its genotoxic and cell proliferation effects. Modeling of a nongenotoxic compound, sodium saccharin (Na S), has also been evaluated. It is not metabolized to a reactive electrophile (it is actually nucleophilic), does not bind to DNA, and is not mutagenic. Nevertheless, in two-generation experiments at high doses it induces a significant incidence of bladder tumors in male rats. It is also a strong tumor-promoting substance following chemical initiation or bladder ulceration. These complex protocols can be readily explained by the proliferative response induced in the urothelium following Na S administration. As expected for a nongenotoxic chemical, there is no effect on the probability of initiation or transformation. Unlike the sodium salt, high doses of the calcium and acid forms of saccharin do not increase cell proliferation significantly, and would not be anticipated to induce tumors. Also, there appears to be a threshold effect related to dose of Na S and the induction of urothelial proliferation. Since cell proliferation is the mechanism by which Na S induces bladder tumors in rats, it is expected that there is also a threshold with respect to carcinogenesis. By allowing for agents to be defined in terms of their ability to affect the genome directly or to act as cell proliferators, model-based analyses provide a rational basis for extrapolating from high doses in animal experiments to low doses in assessing risk for humans.
Collapse
Affiliation(s)
- Samuel M. Cohen
- Professor and Vice-Chairman, Department of Pathology and Microbiology, University of Nebraska Medical Center 42nd and Dewey Avenue Omaha, Nebraska 68105
| | - Leon B. Ellwein
- Professor and Vice-Chairman, Department of Pathology and Microbiology, University of Nebraska Medical Center 42nd and Dewey Avenue Omaha, Nebraska 68105
| |
Collapse
|
27
|
Luijten M, Olthof ED, Hakkert BC, Rorije E, van der Laan JW, Woutersen RA, van Benthem J. An integrative test strategy for cancer hazard identification. Crit Rev Toxicol 2016; 46:615-39. [PMID: 27142259 DOI: 10.3109/10408444.2016.1171294] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Assessment of genotoxic and carcinogenic potential is considered one of the basic requirements when evaluating possible human health risks associated with exposure to chemicals. Test strategies currently in place focus primarily on identifying genotoxic potential due to the strong association between the accumulation of genetic damage and cancer. Using genotoxicity assays to predict carcinogenic potential has the significant drawback that risks from non-genotoxic carcinogens remain largely undetected unless carcinogenicity studies are performed. Furthermore, test systems already developed to reduce animal use are not easily accepted and implemented by either industries or regulators. This manuscript reviews the test methods for cancer hazard identification that have been adopted by the regulatory authorities, and discusses the most promising alternative methods that have been developed to date. Based on these findings, a generally applicable tiered test strategy is proposed that can be considered capable of detecting both genotoxic as well as non-genotoxic carcinogens and will improve understanding of the underlying mode of action. Finally, strengths and weaknesses of this new integrative test strategy for cancer hazard identification are presented.
Collapse
Affiliation(s)
- Mirjam Luijten
- a Centre for Health Protection, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands
| | - Evelyn D Olthof
- a Centre for Health Protection, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands
| | - Betty C Hakkert
- b Centre for Safety of Substances and Products, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands
| | - Emiel Rorije
- b Centre for Safety of Substances and Products, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands
| | | | - Ruud A Woutersen
- d Netherlands Organization for Applied Scientific Research (TNO) , Zeist , the Netherlands
| | - Jan van Benthem
- a Centre for Health Protection, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands
| |
Collapse
|
28
|
Wood CE, Hukkanen RR, Sura R, Jacobson-Kram D, Nolte T, Odin M, Cohen SM. Scientific and Regulatory Policy Committee (SRPC) Review*. Toxicol Pathol 2015; 43:760-75. [DOI: 10.1177/0192623315576005] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Increased cell proliferation is a central key event in the mode of action for many non-genotoxic carcinogens, and quantitative cell proliferation data play an important role in the cancer risk assessment of many pharmaceutical and environmental compounds. Currently, there is limited unified information on assay standards, reference values, targeted applications, study design issues, and quality control considerations for proliferation data. Here, we review issues in measuring cell proliferation indices, considerations for targeted studies, and applications within current risk assessment frameworks. As the regulatory environment moves toward more prospective evaluations based on quantitative pathway-based models, standardization of proliferation assays will become an increasingly important part of cancer risk assessment. To help address this development, we also discuss the potential role for proliferation data as a component of alternative carcinogenicity testing models. This information should improve consistency of cell proliferation methods and increase efficiency of targeted testing strategies.
Collapse
Affiliation(s)
- Charles E. Wood
- U.S. Environmental Protection Agency, Research Triangle Park, North Carolina, USA
| | | | | | - David Jacobson-Kram
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA
- Current Affiliation: NDA Partners, LLC, Rochelle, Virginia, USA
| | - Thomas Nolte
- Boehringer Ingelheim Pharma GmbH & Co., KG Development, Biberach an der Riss, Germany
| | | | | |
Collapse
|
29
|
Thompson CM, Seiter J, Chappell MA, Tappero RV, Proctor DM, Suh M, Wolf JC, Haws LC, Vitale R, Mittal L, Kirman CR, Hays SM, Harris MA. Synchrotron-based imaging of chromium and γ-H2AX immunostaining in the duodenum following repeated exposure to Cr(VI) in drinking water. Toxicol Sci 2015; 143:16-25. [PMID: 25352572 PMCID: PMC4274380 DOI: 10.1093/toxsci/kfu206] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Current drinking water standards for chromium are for the combined total of both hexavalent and trivalent chromium (Cr(VI) and Cr(III)). However, recent studies have shown that Cr(III) is not carcinogenic to rodents, whereas mice chronically exposed to high levels of Cr(VI) developed duodenal tumors. These findings may suggest the need for environmental standards specific for Cr(VI). Whether the intestinal tumors arose through a mutagenic or non-mutagenic mode of action (MOA) greatly impacts how drinking water standards for Cr(VI) are derived. Herein, X-ray fluorescence (spectro)microscopy (µ-XRF) was used to image the Cr content in the villus and crypt regions of duodena from B6C3F1 mice exposed to 180 mg/l Cr(VI) in drinking water for 13 weeks. DNA damage was also assessed by γ-H2AX immunostaining. Exposure to Cr(VI) induced villus blunting and crypt hyperplasia in the duodenum--the latter evidenced by lengthening of the crypt compartment by ∼2-fold with a concomitant 1.5-fold increase in the number of crypt enterocytes. γ-H2AX immunostaining was elevated in villi, but not in the crypt compartment. µ-XRF maps revealed mean Cr levels >30 times higher in duodenal villi than crypt regions; mean Cr levels in crypt regions were only slightly above background signal. Despite the presence of Cr and elevated γ-H2AX immunoreactivity in villi, no aberrant foci indicative of transformation were evident. These findings do not support a MOA for intestinal carcinogenesis involving direct Cr-DNA interaction in intestinal stem cells, but rather support a non-mutagenic MOA involving chronic wounding of intestinal villi and crypt cell hyperplasia.
Collapse
Affiliation(s)
- Chad M Thompson
- ToxStrategies, Inc., Katy, Texas 77494, U.S. Army Engineer Research and Development Center, Vicksburg, Mississippi 39180, Photon Sciences Department, Brookhaven National Laboratory, Upton, New York 11973, ToxStrategies, Inc., Mission Viejo, California 92692, Experimental Pathology Laboratories, Sterling, Virginia 20166, ToxStrategies, Inc., Austin, Texas 78731, Environmental Standards, Inc., Valley Forge, Pennsylvania 19482, Summit Toxicology, LLP, Orange Village, Ohio 44022 and Summit Toxicology, LLP, Allenspark, Colorado 80510
| | - Jennifer Seiter
- ToxStrategies, Inc., Katy, Texas 77494, U.S. Army Engineer Research and Development Center, Vicksburg, Mississippi 39180, Photon Sciences Department, Brookhaven National Laboratory, Upton, New York 11973, ToxStrategies, Inc., Mission Viejo, California 92692, Experimental Pathology Laboratories, Sterling, Virginia 20166, ToxStrategies, Inc., Austin, Texas 78731, Environmental Standards, Inc., Valley Forge, Pennsylvania 19482, Summit Toxicology, LLP, Orange Village, Ohio 44022 and Summit Toxicology, LLP, Allenspark, Colorado 80510
| | - Mark A Chappell
- ToxStrategies, Inc., Katy, Texas 77494, U.S. Army Engineer Research and Development Center, Vicksburg, Mississippi 39180, Photon Sciences Department, Brookhaven National Laboratory, Upton, New York 11973, ToxStrategies, Inc., Mission Viejo, California 92692, Experimental Pathology Laboratories, Sterling, Virginia 20166, ToxStrategies, Inc., Austin, Texas 78731, Environmental Standards, Inc., Valley Forge, Pennsylvania 19482, Summit Toxicology, LLP, Orange Village, Ohio 44022 and Summit Toxicology, LLP, Allenspark, Colorado 80510
| | - Ryan V Tappero
- ToxStrategies, Inc., Katy, Texas 77494, U.S. Army Engineer Research and Development Center, Vicksburg, Mississippi 39180, Photon Sciences Department, Brookhaven National Laboratory, Upton, New York 11973, ToxStrategies, Inc., Mission Viejo, California 92692, Experimental Pathology Laboratories, Sterling, Virginia 20166, ToxStrategies, Inc., Austin, Texas 78731, Environmental Standards, Inc., Valley Forge, Pennsylvania 19482, Summit Toxicology, LLP, Orange Village, Ohio 44022 and Summit Toxicology, LLP, Allenspark, Colorado 80510
| | - Deborah M Proctor
- ToxStrategies, Inc., Katy, Texas 77494, U.S. Army Engineer Research and Development Center, Vicksburg, Mississippi 39180, Photon Sciences Department, Brookhaven National Laboratory, Upton, New York 11973, ToxStrategies, Inc., Mission Viejo, California 92692, Experimental Pathology Laboratories, Sterling, Virginia 20166, ToxStrategies, Inc., Austin, Texas 78731, Environmental Standards, Inc., Valley Forge, Pennsylvania 19482, Summit Toxicology, LLP, Orange Village, Ohio 44022 and Summit Toxicology, LLP, Allenspark, Colorado 80510
| | - Mina Suh
- ToxStrategies, Inc., Katy, Texas 77494, U.S. Army Engineer Research and Development Center, Vicksburg, Mississippi 39180, Photon Sciences Department, Brookhaven National Laboratory, Upton, New York 11973, ToxStrategies, Inc., Mission Viejo, California 92692, Experimental Pathology Laboratories, Sterling, Virginia 20166, ToxStrategies, Inc., Austin, Texas 78731, Environmental Standards, Inc., Valley Forge, Pennsylvania 19482, Summit Toxicology, LLP, Orange Village, Ohio 44022 and Summit Toxicology, LLP, Allenspark, Colorado 80510
| | - Jeffrey C Wolf
- ToxStrategies, Inc., Katy, Texas 77494, U.S. Army Engineer Research and Development Center, Vicksburg, Mississippi 39180, Photon Sciences Department, Brookhaven National Laboratory, Upton, New York 11973, ToxStrategies, Inc., Mission Viejo, California 92692, Experimental Pathology Laboratories, Sterling, Virginia 20166, ToxStrategies, Inc., Austin, Texas 78731, Environmental Standards, Inc., Valley Forge, Pennsylvania 19482, Summit Toxicology, LLP, Orange Village, Ohio 44022 and Summit Toxicology, LLP, Allenspark, Colorado 80510
| | - Laurie C Haws
- ToxStrategies, Inc., Katy, Texas 77494, U.S. Army Engineer Research and Development Center, Vicksburg, Mississippi 39180, Photon Sciences Department, Brookhaven National Laboratory, Upton, New York 11973, ToxStrategies, Inc., Mission Viejo, California 92692, Experimental Pathology Laboratories, Sterling, Virginia 20166, ToxStrategies, Inc., Austin, Texas 78731, Environmental Standards, Inc., Valley Forge, Pennsylvania 19482, Summit Toxicology, LLP, Orange Village, Ohio 44022 and Summit Toxicology, LLP, Allenspark, Colorado 80510 ToxStrategies, Inc., Katy, Texas 77494, U.S. Army Engineer Research and Development Center, Vicksburg, Mississippi 39180, Photon Sciences Department, Brookhaven National Laboratory, Upton, New York 11973, ToxStrategies, Inc., Mission Viejo, California 92692, Experimental Pathology Laboratories, Sterling, Virginia 20166, ToxStrategies, Inc., Austin, Texas 78731, Environmental Standards, Inc., Valley Forge, Pennsylvania 19482, Summit Toxicology, LLP, Orange Village, Ohio 44022 and Summit Toxicology, LLP, Allenspark, Colorado 80510
| | - Rock Vitale
- ToxStrategies, Inc., Katy, Texas 77494, U.S. Army Engineer Research and Development Center, Vicksburg, Mississippi 39180, Photon Sciences Department, Brookhaven National Laboratory, Upton, New York 11973, ToxStrategies, Inc., Mission Viejo, California 92692, Experimental Pathology Laboratories, Sterling, Virginia 20166, ToxStrategies, Inc., Austin, Texas 78731, Environmental Standards, Inc., Valley Forge, Pennsylvania 19482, Summit Toxicology, LLP, Orange Village, Ohio 44022 and Summit Toxicology, LLP, Allenspark, Colorado 80510 ToxStrategies, Inc., Katy, Texas 77494, U.S. Army Engineer Research and Development Center, Vicksburg, Mississippi 39180, Photon Sciences Department, Brookhaven National Laboratory, Upton, New York 11973, ToxStrategies, Inc., Mission Viejo, California 92692, Experimental Pathology Laboratories, Sterling, Virginia 20166, ToxStrategies, Inc., Austin, Texas 78731, Environmental Standards, Inc., Valley Forge, Pennsylvania 19482, Summit Toxicology, LLP, Orange Village, Ohio 44022 and Summit Toxicology, LLP, Allenspark, Colorado 80510 ToxStrategies, Inc., Katy, Texas 77494, U.S. Army Engineer Research and Development Center, Vicksburg, Mississippi 39180, Photon Sciences Department, Brookhaven National Laboratory, Upton, New York 11973, ToxStrategies, Inc., Mission Viejo, California 92692, Experimental Pathology Laboratories, Sterling, Virginia 20166, ToxStrategies, Inc., Austin, Texas 78731, Environmental Standards, Inc., Valley Forge, Pennsylvania 19482, Summit Toxicology, LLP, Orange Village, Ohio 44022 and Summit Toxicology, LLP, Allenspark, Colorado 80510
| | - Liz Mittal
- ToxStrategies, Inc., Katy, Texas 77494, U.S. Army Engineer Research and Development Center, Vicksburg, Mississippi 39180, Photon Sciences Department, Brookhaven National Laboratory, Upton, New York 11973, ToxStrategies, Inc., Mission Viejo, California 92692, Experimental Pathology Laboratories, Sterling, Virginia 20166, ToxStrategies, Inc., Austin, Texas 78731, Environmental Standards, Inc., Valley Forge, Pennsylvania 19482, Summit Toxicology, LLP, Orange Village, Ohio 44022 and Summit Toxicology, LLP, Allenspark, Colorado 80510
| | - Christopher R Kirman
- ToxStrategies, Inc., Katy, Texas 77494, U.S. Army Engineer Research and Development Center, Vicksburg, Mississippi 39180, Photon Sciences Department, Brookhaven National Laboratory, Upton, New York 11973, ToxStrategies, Inc., Mission Viejo, California 92692, Experimental Pathology Laboratories, Sterling, Virginia 20166, ToxStrategies, Inc., Austin, Texas 78731, Environmental Standards, Inc., Valley Forge, Pennsylvania 19482, Summit Toxicology, LLP, Orange Village, Ohio 44022 and Summit Toxicology, LLP, Allenspark, Colorado 80510 ToxStrategies, Inc., Katy, Texas 77494, U.S. Army Engineer Research and Development Center, Vicksburg, Mississippi 39180, Photon Sciences Department, Brookhaven National Laboratory, Upton, New York 11973, ToxStrategies, Inc., Mission Viejo, California 92692, Experimental Pathology Laboratories, Sterling, Virginia 20166, ToxStrategies, Inc., Austin, Texas 78731, Environmental Standards, Inc., Valley Forge, Pennsylvania 19482, Summit Toxicology, LLP, Orange Village, Ohio 44022 and Summit Toxicology, LLP, Allenspark, Colorado 80510 ToxStrategies, Inc., Katy, Texas 77494, U.S. Army Engineer Research and Development Center, Vicksburg, Mississippi 39180, Photon Sciences Department, Brookhaven National Laboratory, Upton, New York 11973, ToxStrategies, Inc., Mission Viejo, California 92692, Experimental Pathology Laboratories, Sterling, Virginia 20166, ToxStrategies, Inc., Austin, Texas 78731, Environmental Standards, Inc., Valley Forge, Pennsylvania 19482, Summit Toxicology, LLP, Orange Village, Ohio 44022 and Summit Toxicology, LLP, Allenspark, Colorado 80510 ToxStrategies, Inc., Katy, Texas 77494, U.S. Army Engineer Research and Development Center, Vicksburg, Mississippi 39180, Photon Sciences Department, Brookhaven National Laboratory, Upton, New York 11973, ToxStrategies, Inc., Mission Viejo, California 92692, Experimental Pathology Laboratories, Sterling, Virginia 20166, ToxStrategies, Inc., Austin, Texas 78731, Environmental Standards, Inc
| | - Sean M Hays
- ToxStrategies, Inc., Katy, Texas 77494, U.S. Army Engineer Research and Development Center, Vicksburg, Mississippi 39180, Photon Sciences Department, Brookhaven National Laboratory, Upton, New York 11973, ToxStrategies, Inc., Mission Viejo, California 92692, Experimental Pathology Laboratories, Sterling, Virginia 20166, ToxStrategies, Inc., Austin, Texas 78731, Environmental Standards, Inc., Valley Forge, Pennsylvania 19482, Summit Toxicology, LLP, Orange Village, Ohio 44022 and Summit Toxicology, LLP, Allenspark, Colorado 80510
| | - Mark A Harris
- ToxStrategies, Inc., Katy, Texas 77494, U.S. Army Engineer Research and Development Center, Vicksburg, Mississippi 39180, Photon Sciences Department, Brookhaven National Laboratory, Upton, New York 11973, ToxStrategies, Inc., Mission Viejo, California 92692, Experimental Pathology Laboratories, Sterling, Virginia 20166, ToxStrategies, Inc., Austin, Texas 78731, Environmental Standards, Inc., Valley Forge, Pennsylvania 19482, Summit Toxicology, LLP, Orange Village, Ohio 44022 and Summit Toxicology, LLP, Allenspark, Colorado 80510
| |
Collapse
|
30
|
|
31
|
Da Rocha MS, Arnold LL, De Oliveira MLCS, Catalano SMI, Cardoso APF, Pontes MGN, Ferrucio B, Dodmane PR, Cohen SM, De Camargo JLV. Diuron-induced rat urinary bladder carcinogenesis: Mode of action and human relevance evaluations using the International Programme on Chemical Safety framework. Crit Rev Toxicol 2014; 44:393-406. [DOI: 10.3109/10408444.2013.877870] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
32
|
Cohen SM, Arnold LL, Beck BD, Lewis AS, Eldan M. Evaluation of the carcinogenicity of inorganic arsenic. Crit Rev Toxicol 2013; 43:711-52. [DOI: 10.3109/10408444.2013.827152] [Citation(s) in RCA: 123] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
33
|
Kleinstreuer NC, Dix DJ, Houck KA, Kavlock RJ, Knudsen TB, Martin MT, Paul KB, Reif DM, Crofton KM, Hamilton K, Hunter R, Shah I, Judson RS. In Vitro Perturbations of Targets in Cancer Hallmark Processes Predict Rodent Chemical Carcinogenesis. Toxicol Sci 2012; 131:40-55. [DOI: 10.1093/toxsci/kfs285] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Strupp C, Banas DA, Cohen SM, Gordon EB, Jaeger M, Weber K. Relationship of metabolism and cell proliferation to the mode of action of fluensulfone-induced mouse lung tumors: analysis of their human relevance using the IPCS framework. Toxicol Sci 2012; 128:284-94. [PMID: 22491425 PMCID: PMC3391030 DOI: 10.1093/toxsci/kfs127] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Species-specific lung tumors in the mouse are induced by a number of chemicals. The underlying cause appears to be a high metabolic activity of mouse lung, due to relatively high abundance of Clara cells in mice compared with humans and the mouse-specific cytochrome P450 isoform 2f2 in the Clara cells. The chemicals are activated to reactive intermediates, leading to local cytotoxicity or mitogenicity resulting in increased cell proliferation and tumors. Rats have lower metabolic activity than mice (already below the threshold needed to cause lung tumors upon lifetime exposure) and activity in humans is lower than in rats. The carcinogenic risk for human lung is low for this mode of action (MOA). Fluensulfone has shown an increased incidence of lung adenomas in mice, but not in rats, at high doses. Fluensulfone is not genotoxic. MOA studies were conducted investigating key events of the postulated MOA. Fluensulfone is extensively metabolized by mouse lung microsomes, whereas no metabolic activity is seen with human lung microsomes. Cyp 2f2 is a major contributor in fluensulfone’s metabolism and Cyp 2e1 is not involved. Furthermore, administration of fluensulfone to mice led to an early increase in Clara cell proliferation. The International Programme on Chemical Safety (IPCS) MOA and human relevance framework was used to evaluate the collective data on fluensulfone. We concluded that fluensulfone leads to species-specific mouse lung tumors and that these tumors are likely not relevant to human hazard or risk.
Collapse
Affiliation(s)
- Christian Strupp
- Makhteshim Agan Holding B.V., Schaffhausen Branch, 8200 Schaffhausen, Switzerland.
| | | | | | | | | | | |
Collapse
|
35
|
Cohen SM. Urinary Bladder Carcinogenesis by DNA Reactive and Non-Reactive Chemicals: Non-Linearities and Thresholds. Genes Environ 2012. [DOI: 10.3123/jemsge.34.165] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
36
|
Kakiuchi-Kiyota S, Arnold LL, Yokohira M, Suzuki S, Pennington KL, Cohen SM. Evaluation of PPARγ agonists on rodent endothelial cell proliferation. Toxicology 2011; 287:91-8. [DOI: 10.1016/j.tox.2011.05.019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2011] [Revised: 05/26/2011] [Accepted: 05/30/2011] [Indexed: 10/18/2022]
|
37
|
Wisler JA, Afshari C, Fielden M, Zimmermann C, Taylor S, Carnahan J, Vonderfecht S. Raf Inhibition Causes Extensive Multiple Tissue Hyperplasia and Urinary Bladder Neoplasia in the Rat. Toxicol Pathol 2011; 39:809-22. [DOI: 10.1177/0192623311410442] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Seven novel and potent Raf small molecule kinase inhibitors (C1–7) were evaluated in seven-day oral repeat dose rat toxicity studies. All compounds tested induced hyperplasia in multiple tissues. Consistently affected was stratified squamous epithelium at a number of sites and transitional epithelium of urinary bladder and kidney. A seven-day time course study in rats showed morphologic evidence of epithelial proliferation in the nonglandular stomach within four to five hours after a single dose of C-1. Similar indications of cellular proliferation were observed in the urinary bladder by day 2 and in the heart, kidney, and liver by day 3. Transcriptional evidence of proliferation in the urinary bladder was detected within four to five hours after a single dose consistent with activation of the PI3K/AKT and ERK/MAPK pathways. In a twenty-eight-day rat toxicity study of C-1, hyperplasia was observed in the esophagus, nonglandular stomach, skin, urinary bladder, kidney, and heart. Hyperplasia of transitional epithelium of the urinary bladder was particularly severe and in one female rat was accompanied by the presence of a transitional cell carcinoma. These results suggest that these Raf inhibitors induce early transcriptional changes driving unchecked cell proliferation, resulting in marked tissue hyperplasia that can progress to carcinoma within a short time frame.
Collapse
Affiliation(s)
- John A. Wisler
- Comparative Biology Safety Sciences, Amgen Inc., Thousand Oaks, California, USA
| | - Cynthia Afshari
- Comparative Biology Safety Sciences, Amgen Inc., Thousand Oaks, California, USA
| | - Mark Fielden
- Comparative Biology Safety Sciences, Amgen Inc., Thousand Oaks, California, USA
| | - Cameron Zimmermann
- Comparative Biology Safety Sciences, Amgen Inc., Thousand Oaks, California, USA
| | - Scott Taylor
- Comparative Biology Safety Sciences, Amgen Inc., Thousand Oaks, California, USA
| | - Josette Carnahan
- Departments of Hematology & Oncology Research, Amgen Inc., Thousand Oaks, California, USA
| | - Steven Vonderfecht
- Comparative Biology Safety Sciences, Amgen Inc., Thousand Oaks, California, USA
| |
Collapse
|
38
|
Abstract
Understanding the relationship of chemicals to carcinogenesis has progressed significantly since the initial observations of Hill and Pott in the 1700's. Distinguishing between DNA-reactive chemicals and those which increase cancer risk by increasing cell proliferation has been a major breakthrough in delineating overall mechanisms. Competing processes for activation versus inactivation of chemicals occur at many levels, including metabolism, DNA repair, and cellular repair processes. These processes can be affected by other agents to decrease carcinogenesis (chemoprevention). Increasing knowledge of the multiple steps of carcinogenesis is leading to improved methods for screening chemicals for carcinogenic activity and for regulatory decision making. Improvements in assessment of modes of action involved in animal and in vitro models have led to more rational approaches to assessing relevance to humans. The advent of genomics and high-throughput technologies have contributed to investigations of mechanisms and is beginning to impact development of better methods for screening chemicals. Based on developments in basic research, epidemiology, and astute clinical observations, the major risk factors and etiologic agents have been identified for a majority of cancers, which is beginning to lead to methods to decrease cancer incidence overall and identify targets for early detection and treatment.
Collapse
Affiliation(s)
- Samuel M Cohen
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska 68198-3135, USA.
| | | |
Collapse
|
39
|
Cohen SM, Gordon EB, Singh P, Arce GT, Nyska A. Carcinogenic mode of action of folpet in mice and evaluation of its relevance to humans. Crit Rev Toxicol 2010; 40:531-45. [DOI: 10.3109/10408441003742903] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
40
|
Cohen SM. Evaluation of Possible Carcinogenic Risk to Humans Based on Liver Tumors in Rodent Assays. Toxicol Pathol 2010; 38:487-501. [DOI: 10.1177/0192623310363813] [Citation(s) in RCA: 92] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The two-year rodent bioassay remains the mainstay for carcinogenicity testing, although numerous difficulties have been identified. Fundamentally, a chemical can increase the risk of cancer (1) by damaging DNA directly (DNA reactive) or (2) indirectly by increasing the number of DNA replications (non–DNA reactive). Mechanistic research has identified numerous precursor lesions in the sequence of key events necessary for neoplasia development. Based on these concepts, the author has proposed a short-term (thirteen-week) assay for screening for carcinogenic potential based on a mode of action analysis and on readily available, identifiable preneoplastic changes. A screening assay that detects all potential rodent hepatocarcinogens has been previously identified ( Toxicol Pathol32 [2004], 393–401) including increased liver weight, hepatocellular necrosis, hypertrophy, and cytomegaly. Labeling index for DNA replication might supply additional support. These markers have high sensitivity but low specificity. However, most chemicals can be appropriately classified as to their mode(s) of action for hepatocarcinogenesis with follow-up mechanistic studies, and a rational evaluation of their relevance to humans can be made. A similar process can be envisioned for other tissues for evaluation for carcinogenic potential.
Collapse
Affiliation(s)
- Samuel M. Cohen
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE
| |
Collapse
|
41
|
Boobis AR, Cohen SM, Doerrer NG, Galloway SM, Haley PJ, Hard GC, Hess FG, Macdonald JS, Thibault S, Wolf DC, Wright J. A Data-Based Assessment of Alternative Strategies for Identification of Potential Human Cancer Hazards. Toxicol Pathol 2009; 37:714-32. [DOI: 10.1177/0192623309343779] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
The two-year cancer bioassay in rodents remains the primary testing strategy for in-life screening of compounds that might pose a potential cancer hazard. Yet experimental evidence shows that cancer is often secondary to a biological precursor effect, the mode of action is sometimes not relevant to humans, and key events leading to cancer in rodents from nongenotoxic agents usually occur well before tumorigenesis and at the same or lower doses than those producing tumors. The International Life Sciences Institute (ILSI) Health and Environmental Sciences Institute (HESI) hypothesized that the signals of importance for human cancer hazard identification can be detected in shorter-term studies. Using the National Toxicology Program (NTP) database, a retrospective analysis was conducted on sixteen chemicals with liver, lung, or kidney tumors in two-year rodent cancer bioassays, and for which short-term data were also available. For nongenotoxic compounds, results showed that cellular changes indicative of a tumorigenic endpoint can be identified for many, but not all, of the chemicals producing tumors in two-year studies after thirteen weeks utilizing conventional endpoints. Additional endpoints are needed to identify some signals not detected with routine evaluation. This effort defined critical questions that should be explored to improve the predictivity of human carcinogenic risk.
Collapse
Affiliation(s)
| | | | - Nancy G. Doerrer
- ILSI Health and Environmental Sciences Institute, Washington, D.C., 20005 USA
| | | | | | | | | | | | | | - Douglas C. Wolf
- U.S. Environmental Protection Agency, Research Triangle Park, NC, 27713 USA
| | | |
Collapse
|
42
|
Melatonin prevents the development of hyperplastic urothelium induced by repeated doses of cyclophosphamide. Virchows Arch 2009; 454:657-66. [PMID: 19381685 DOI: 10.1007/s00428-009-0765-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2008] [Revised: 02/14/2009] [Accepted: 03/19/2009] [Indexed: 10/20/2022]
Abstract
Repeated cyclophosphamide (CP) chemotherapy increases the risk of developing bladder cancer, which could be due to the extremely rapid proliferation of urothelial cells observed in hyperplastic urothelium induced by CP treatment. We investigated the effect of melatonin on the development of urothelial hyperplasia induced by repeated CP treatment. Male ICR mice were injected with CP (150 mg/kg) or melatonin (10 mg/kg) with CP once a week for 3, 4 and 5 weeks. Transmission and scanning electron microscopy, immunohistochemistry and Western blot analysis were used to study the ultrastructure, apoptosis, proliferation and differentiation of urothelial cells. Repeated doses of CP caused the development of hyperplastic urothelium with up to ten cell layers and increased proliferation and apoptotic indices regarding Ki-67 and active caspase-3 immunohistochemistry, respectively. Scanning electron microscopy observations, cytokeratin and asymmetrical unit membrane immunohistochemistry and Western blot analysis showed a lower differentiation state of superficial urothelial cells. Melatonin co-treatment prevented the development of hyperplastic urothelium, statistically significantly decreased proliferation and apoptotic indices after four and five doses of CP and caused higher differentiation state of superficial urothelial cells.
Collapse
|
43
|
|
44
|
Affiliation(s)
- Samuel M. Cohen
- Department of Pathology and Microbiology and the Eppley Institute for Research on Cancer, University of Nebraska Medical Center
| | - Lora L. Arnold
- Department of Pathology and Microbiology and the Eppley Institute for Research on Cancer, University of Nebraska Medical Center
| |
Collapse
|
45
|
Cohen SM. Thresholds in Genotoxicity and Carcinogenicity: Urinary Bladder Carcinogenesis. Genes Environ 2008. [DOI: 10.3123/jemsge.30.132] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
46
|
Affiliation(s)
- S M Cohen
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha 68198-3135, USA
| |
Collapse
|
47
|
Kramer DA, Conolly RB. Computer simulation of clonal growth cancer models. I. Parameter estimation using an iterative absolute bisection algorithm. RISK ANALYSIS : AN OFFICIAL PUBLICATION OF THE SOCIETY FOR RISK ANALYSIS 1997; 17:115-126. [PMID: 9131830 DOI: 10.1111/j.1539-6924.1997.tb00850.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
Quantitative models of the relationship between exposure to chemical carcinogens and carcinogenic response are useful for hypothesis evaluation and risk assessment. The degree to which such models accurately depict the underlying biology is often a function of the need for mathematical tractability. When closed-form expressions are used, the need for tractability may significantly limit their complexity. This problem can be minimized by using numerical computer simulation methods to solve the model, thereby allowing more complex and realistic descriptions of the biology to be used. Unfortunately, formal methods of parameter estimation for numerical models are not as well developed as they are for analytical models. In this report, we develop a formal parameter estimation routine and apply it to a numerical clonal growth simulation (CGS) model of the growth of preneoplastic lesions consisting of initiated cells. An iterative bisection algorithm was used to estimate parameters from time-course data on the number of initiated cells and the number of clones of these cells. The algorithm successfully estimated parameter values to give a best fit to the observed dataset and was robust vis-à-vis starting values of the parameters. Furthermore, the number of data points to which the model was fit, the number of stochastic repetitions and other variables were examined with respect to their effects on the parameter estimates. This algorithm facilitates the application of CGS models for hypothesis evaluation and risk assessment by ensuring uniformity and reproducibility of parameter estimates.
Collapse
Affiliation(s)
- D A Kramer
- Chemical Industry Institute of Toxicology, Research Triangle Park, North Carolina 27709, USA
| | | |
Collapse
|
48
|
Portier CJ, Kopp-Schneider A, Sherman CD. Calculating tumor incidence rates in stochastic models of carcinogenesis. Math Biosci 1996; 135:129-46. [PMID: 8768218 DOI: 10.1016/0025-5564(96)00011-9] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Multistage models of carcinogenesis are increasingly used in the estimation of risks from exposure to environmental agents. The two-stage model of carcinogenesis is routinely used because it agrees with much of the existing tumor incidence data, parallels the biological two-stage model, and has much of its mathematical details derived. However, recent findings on the mechanisms of carcinogenesis has led researchers to believe that there are a greater number of stages and a more complex structure to these models than a single pathway. In this paper, a method for readily computing tumor incidence rates for arbitrarily complex multistage models is derived. The formulas for the two-stage model with time-varying rates are given explicitly. Simple rules for more complicated models are given, and computer code able to implement these formulas are provided.
Collapse
Affiliation(s)
- C J Portier
- National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA
| | | | | |
Collapse
|
49
|
Abstract
Stochastic mathematical models of carcinogenesis have been used to quantify cancer risks for about 40 years. As more detailed data of the cancer process are obtained, mathematical models try to incorporate this information and as a result become more complex and sometimes analytically and numerically intractable. Simulation studies have become an important tool for examining the operating characteristics of the models of interest. The many quantities one can examine using this tool include bias in parameter estimates, adequacy of approximation methods, and the appropriateness of large sample generalizations to small studies. This manuscript describes a general method of stochastic simulation that may be carried out for arbitrarily complicated stochastic models of carcinogenesis.
Collapse
Affiliation(s)
- C D Sherman
- Laboratory of Quantitative and Computational Biology, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA
| | | |
Collapse
|
50
|
Abstract
Chemicals can increase carcinogenic risk by either directly damaging DNA or increasing cell replication or they can do both. These effects have different implications for a biologically-based extrapolation from rodent bioassays to humans. 2-Acetylaminofluorene (2-AAF) administered at low doses to mice for a lifetime has a different dose-response for the liver (approximately linear) compared to the urinary bladder (apparent no effect dose of 45 ppm with a sigmoidal dose response at 60-150 ppm), which can be explained if carcinogen metabolism, DNA adduct formation and cell proliferation effects are considered. In contrast to 2-AAF and other genotoxic chemicals, chemicals which form calculi in the urine do not generally damage DNA directly but increase cell proliferation dramatically by eroding the bladder surface, leading to regenerative hyperplasia. This occurs only at doses at which calculi form; lower doses do not produce calculi and, therefore, do not increase cell proliferation or cause tumors. Extrapolation to humans from the rodent bioassay should be dependent on dose requirements for formation of calculi rather than any type of statistical extrapolation to lower doses. Saccharin and other sodium salts administered at high doses to rats also produce bladder cancer by increasing cell proliferation. These salts do not affect mice, hamsters, guinea pig or monkeys. Based on dose and mechanistic considerations, saccharin and these other sodium salts are unlikely to be human carcinogens. Extrapolation to possible human cancer risk requires biological determinations rather than simply using statistical formulations.
Collapse
Affiliation(s)
- S M Cohen
- University of Nebraska Medical Center, Department of Pathology and Microbiology, Omaha 68198-3135, USA
| |
Collapse
|